HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
Authors: Kawagishi, Naoki Browse this author
Suda, Goki Browse this author →KAKEN DB
Yamamoto, Yoshiya Browse this author
Baba, Masaru Browse this author
Furuya, Ken Browse this author
Maehara, Osamu Browse this author
Ohnishi, Shunsuke Browse this author
Yoshida, Sonoe Browse this author
Fu, Qingjie Browse this author
Yang, Zijian Browse this author
Hosoda, Shunichi Browse this author
Tokuchi, Yoshimasa Browse this author
Kitagataya, Takashi Browse this author
Ohara, Masatsugu Browse this author
Suzuki, Kazuharu Browse this author
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Natsuizaka, Mitsuteru Browse this author
Ogawa, Koji Browse this author
Sakamoto, Naoya Browse this author
Keywords: hepatitis C virus
direct-acting antiviral
hepatocellular carcinoma
Issue Date: Jan-2023
Publisher: MDPI
Journal Title: Viruses-Basel
Volume: 15
Issue: 1
Start Page: 181
Publisher DOI: 10.3390/v15010181
Abstract: Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age >= 75 years (HR: 2.92, 95% CI: 1.34-6.33; p = 0.007) and baseline Ang2 level >= 464 pg/mL (HR: 2.75, 95% CI: 1.18-6.37; p = 0.019) were significantly associated with HCC occurrence after DAA therapy. A high or low risk of HCC after DAA therapy could be distinguished by the combination of age and baseline Ang2 level. The cumulative incidences of de-novo HCC at two and four years were 0.8% and 3.8% in the low-risk group and 22.6% and 27.1% in the high-risk group, respectively. Baseline Ang2 level >= 402 pg/mL was significantly associated with HCC recurrence in patients who achieved sustained virological response with DAAs (HR: 3.68). In conclusion, serum Ang2 levels can predict HCC occurrence and recurrence after successful HCV eradication by DAAs.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University